The novel potential of statins as HDAC inhibitors may be particularly relevant to diabetic nephropathy since diabetes has been associated with increase in HDAC activity in renal tissues, i.e., gene-specific transcriptional regulation was reportedly altered in diabetic kidneys via reducing acetylation of histone tails23, 24, 25. The gene discussed is HDAC9; the disease is diabetic kidney disease.